Diagnosis and prognostic value of markers of oncogenesis in patients with hyperplastic endometrial processes with uterine fibroids
Keywordsendometrial hyperplastic processes, uterine fibroids, biomarkers, survivin
Introduction: The relevance of the study of the problem of endometrial hyperplastic processes (EHP) is due primarily to the high risk of malignancy of this pathology and its recurrent course. Despite numerous studies on EHP, some issues of pathogenesis, diagnosis and treatment of this pathology remain debatable.
Objective: To evaluate the levels of APRIL, survinin and phosphoPTEN in serum of women with various forms of EHP in combination with uterine fibroids and their prognostic value for recurrence.
Materials and Methods: 105 women with endometrial hyperplastic processes and endometrial adenocarcinoma were examined during the study. The first group consisted of 34 women with simple endometrial hyperplasia without atypia (SEHWA), the second group included 47 patients with complex endometrial hyperplasia without atypia (CEHWA). The groups were divided into subgroups with or without uterine fibroids. The third group consisted of 26 women with endometrial adenocarcinoma.
Results: Level of APRIL was increased in the CEHWA group compared to the control group (p<0,05) and the SEHWA (p<0,05). Women with endometrial adenocarcinoma had significantly higher APRIL levels compared to controls and patients with both types of endometrial hyperplasia (p<0,05). Women with SEHWA had significantly higher level of survinin compared to controls (p<0,05). Patients with CEHWA and adenocarcinoma had serum levels of survinin higher than those in the control and SEHWA groups (p<0,05).
Conclusions: Adequate prognostic significance for the occurrence of relapses of EHP had the increasing of APRIL level greater than 43 pg/ml and survinin level greater than 70 pg/ml. In patients with EHP in combination with uterine fibroids a significant risk factor for relapse was an increasing of APRIL level greater than 43 pg/ml.
Trimble CL. Management of endometrial precancers. Obstet. Gynecol. 2012; 120 (5): 1160-1175. DOI: http://10.1097/AOG.0b013e31826bb121.
Korniyenko SM. Optymizatsiya likuvannya hiperplastychnykh protsesiv endometriya v pizn'omu reproduktyvnomMu periodi za dopomohoyu histeroskopichnoyi tekhniky «kholodnoyi petli». Gynecology. 2017; 6 (14): 44-49. DOI: http://dx.doi.org/10.18370/2309-4117.2017.35.44-49. Ukrainian.
Vovk IB., Gorban NE., Borisyuk OY. Giperplaziya endometriya (Clinical lecture). Woman's health. 2016; 5: 10-18. Ukrainian.
Korniyenko SM. Hiperplastychni protsesy endometriya u zhinok v pizn'omu reproduktyvnomu i premenopauzal'nomu periodi: shcho vplyvaye na retsydyvy. Bulletin of the Social Hygiene and Health Organization of Ukraine. 2017; 2: 39-47. Ukrainian.
Slyusareva OA. Molekulyarnyye metody diagnostiki giperplazii endometriya. RUDN newspaper. Series: Medicine. 2016; 2: 176-180. Russian.
Dronova VL. Kliniko-anamnestychni osoblyvosti ta yakist' zhyttya zhinok z patolohiyeyu endometriya na foni miomy matky. Medical perspectives. 2017; 22 (1): 81-88. Ukrainian.
Sparic R., Mirkovic L., Malvasi A., Tinelli A. Epidemiology of Uterine Myomas: A Review. Int. J. Fertil Steril. 2016; 9, N 4: 424-435. DOI: 10.22074 / ijfs.2015.4599.
Khan AT., Shehmar M., Gupta JK. Uterine fibroids: current perspectives. Int. J. Womens Health. 2014; 6: 95-114. DOI: 10.2147 / ijwh.s51083.
Arjunan Dr. A., Nilavu Dr.J., Thiriveni Balajji Dr. GS. et al. Expression of Bcl-2 and Ki-67 in Cyclical Endometrium and in Endometrial Hyperplasia - An Analysis. Journal of Dental and Medical Sciences. 2016; 15: 43-49. DOI: 10.9790 / 0853-1504084349.
Abike F., Tapisiz OL., Zergeroglu S. et al. PCNA and KI-67 in endometrial hyperplasias and evaluation of the potential of malignancy. Eur. J. Gynaecol. Oncol. 2011; 32. No. 1: 77-80.
Daud S., Jalil SS, Griffin M. et al. Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 159: 172-175. DOI: 10.1016 / j.ejogrb.2011.06.023.
Ware FC. April and Baff Connect Autoimmunity and Cancer: Figure 1. The Journal Of Experimental Medicine. 2000; 192 (11): F35-F38. DOI: 10.1084 / jem.192.11.f35.
Dubrovina SO., Berlim YD. Markery proliferativnoy aktivnosti i angiogeneza u bol'nykh s giperplasticheskimi protsessami endometriya. Reproduction Issues. 2012; (3): 22-27. Russian.
Erkanli S., Kayaselcuk F., Kuscu E., Bagis T., Bolat F. et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer 2006; 16: 1412-1418. DOI: 10.1111/j.1525-1438.2006.00541.x
Kapucuoglu, N., Aktepe, F., Kaya, H., Bircan, S. et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathology - Research And Practice. 2007; 203 (3): 153-162. DOI: 10.1016 / j.prp.2007.01.003.
Lacey JVJr., Mutter GL. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res. 2008; 68 (14): 6014-20. DOI: 10.1158/0008-5472.CAN-08-1154.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 142
Number of citations: 0